46.70
4.17%
1.87
Handel nachbörslich:
46.70
Agios Pharmaceuticals Inc Aktie (AGIO) Neueste Nachrichten
Agios to Present New Data on Mitapivat and Tebapivat in Rare Blood Disorders at 66th ASH Annual Meeting and Exposition - The Manila Times
Agios to Unveil Critical Phase 3 Data for Blood Disorder Drugs at ASH 2024 | AGIO Stock News - StockTitan
Agios Pharmaceuticals' SWOT analysis: promising pipeline, cash boost fuel stock outlook - Investing.com
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Shares Sold by Assenagon Asset Management S.A. - MarketBeat
Agios Pharmaceuticals (NASDAQ:AGIO) Rating Lowered to “Sell” at StockNews.com - Defense World
Agios Pharmaceuticals (NASDAQ:AGIO) Downgraded to "Sell" Rating by StockNews.com - MarketBeat
Deep Dive Into Alnylam Pharmaceuticals Stock: Analyst Perspectives (6 Ratings) - Benzinga
Agios Pharmaceuticals (NASDAQ:AGIO) Given "Outperform" Rating at Royal Bank of Canada - MarketBeat
AGIO's Q3 Earnings Miss Mark, Revenues In Line, Stock Down - Yahoo Finance
Agios Pharmaceuticals (NASDAQ:AGIO) Given New $53.00 Price Target at Scotiabank - MarketBeat
Agios shares hold Strong Buy rating, $51 target from Raymond James - Investing.com Australia
Is ADC Therapeutics (ADCT) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Agios Pharmaceuticals Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Q3 2024 Earnings Call Transcript - Insider Monkey
Agios Pharmaceuticals Inc (AGIO) Q3 2024 Earnings Call Highlights: Strong Cash Position and ... - Yahoo Finance
Agios Pharmaceuticals Inc (AGIO) Q3 2024 Earnings Call Highlights: Strong Cash Position and Strategic Advancements - GuruFocus.com
Agios Pharmaceuticals: Q3 Earnings Snapshot - The Advocate
Agios Pharmaceuticals Reports Robust Q3 2024 Results - TipRanks
Agios Pharmaceuticals (AGIO) Misses Q3 Earnings and Revenue Estimates - MSN
Agios Pharmaceuticals Inc (AGIO) Q3 2024 Earnings: EPS Surpasses Estimates, Revenue at $9.0 Million - GuruFocus.com
Agios Reports Business Highlights and Third Quarter 2024 Financial Results - The Manila Times
Earnings Preview: Agios Pharmaceuticals - Benzinga
Leerink Partnrs Issues Optimistic Estimate for AGIO Earnings - MarketBeat
Analysts Are Optimistic We'll See A Profit From Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) - Simply Wall St
Equities Analysts Set Expectations for AGIO Q3 Earnings - MarketBeat
Pfizer Pulls Key Sickle Cell Drug Over Safety Concerns - Finimize
Agios Pharmaceuticals' SWOT analysis: stock outlook amid SCD market shifts By Investing.com - Investing.com Australia
Agios Pharmaceuticals (AGIO) Set to Announce Quarterly Earnings on Thursday - MarketBeat
Agios Pharmaceuticals' SWOT analysis: stock outlook amid SCD market shifts - Investing.com India
Servier vorasidenib PDUFA near, Agios wins in thalassemia - BioWorld Online
Agios completes enrollment for sickle cell disease trial By Investing.com - Investing.com Canada
Agios completes enrollment for sickle cell disease trial - Investing.com
Agios Completes Enrollment of Phase 3 RISE UP Study of Mitapivat in Sickle Cell Disease - The Manila Times
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
(AGIO) Investment Report - Stock Traders Daily
Agios to Webcast Conference Call of Third Quarter 2024 Financial Results on October 31, 2024 - StockTitan
Agios to Webcast Conference Call of Third Quarter 2024 Financial Results on October 31, 2024 - GlobeNewswire Inc.
Agios Pharmaceuticals (NASDAQ:AGIO) Upgraded by StockNews.com to Hold - MarketBeat
Scotiabank Initiates Coverage on Agios Pharmaceuticals (NASDAQ:AGIO) - MarketBeat
Beta Thalassemia Market to Show Remarkable Growth Trends from - openPR
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Short Interest Update - MarketBeat
Leerink keeps market perform rating on Agios Pharma shares amid SCD drug concerns - Investing.com Canada
SG Americas Securities LLC Invests $705,000 in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) - MarketBeat
Novavax And Agios Pharmaceuticals Were Among The 10 Biggest Mid-Cap Gainers Last Week (June 1-June 7): Are These In Your Portfolio? - MSN
AQR Capital Management LLC Increases Stake in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) - MarketBeat
Agios Pharma stock raised to Outperform By Investing.com - Investing.com UK
4 Analysts Have This To Say About Agios Pharmaceuticals - Benzinga
Raymond James Reiterates Outperform Rating for Agios Pharmaceuticals (NASDAQ:AGIO) - MarketBeat
Sei Investments Co. Takes Position in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) - MarketBeat
The Manufacturers Life Insurance Company Has $5.94 Million Stock Holdings in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) - MarketBeat
Alpha Thalassemia Pipeline Dynamics 2024: FDA Approvals, Therapeutic Advances, MOA, ROA by DelveInsight | Genmedicn Biopharma Ltd., Bristol-Myers Squibb, Agios Pharma - Barchart
Agios Pharmaceuticals CFO sells shares worth $124,634 - Investing.com India
Agios Pharmaceuticals CFO sells shares worth $124,634 By Investing.com - Investing.com South Africa
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Kapitalisierung:
|
Volumen (24h):